These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 17468644)

  • 61. Rotavirus vaccination coverage and adherence to the Advisory Committee on Immunization Practices (ACIP)-recommended vaccination schedule--United States, February 2006-May 2007.
    ;
    MMWR Morb Mortal Wkly Rep; 2008 Apr; 57(15):398-401. PubMed ID: 18418345
    [TBL] [Abstract][Full Text] [Related]  

  • 62. MCV vaccination in the presence of vaccine-associated Guillain-Barré Syndrome risk: a decision analysis approach.
    Cho BH; Clark TA; Messonnier NE; Ortega-Sanchez IR; Weintraub E; Messonnier ML
    Vaccine; 2010 Jan; 28(3):817-22. PubMed ID: 19879992
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Quadrivalent meningococcal conjugate vaccines.
    Pace D; Pollard AJ; Messonier NE
    Vaccine; 2009 Jun; 27 Suppl 2():B30-41. PubMed ID: 19477560
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Safety and immunogenicity of the tetravalent protein-conjugated meningococcal vaccine (MCV4) in recipients of related and unrelated allogeneic hematopoietic stem cell transplantation.
    Mahler MB; Taur Y; Jean R; Kernan NA; Prockop SE; Small TN
    Biol Blood Marrow Transplant; 2012 Jan; 18(1):145-9. PubMed ID: 21820392
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Reconsideration of the use of meningococcal polysaccharide vaccine.
    Granoff DM; Pollard AJ
    Pediatr Infect Dis J; 2007 Aug; 26(8):716-22. PubMed ID: 17848884
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Notes from the Field: Administration Error Involving a Meningococcal Conjugate Vaccine--United States, March 1, 2010-September 22, 2015.
    Su JR; Miller ER; Duffy J; Baer BM; Cano MV
    MMWR Morb Mortal Wkly Rep; 2016 Feb; 65(6):161-2. PubMed ID: 26890604
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Analysis of mortality following a mass immunization campaign with serogroup C meningococcal conjugate vaccine: methodological difficulties and imperfect solutions.
    De Wals P; Deceuninck G; Ouakki M; Boulianne N; De Serres G; Danzig L
    Vaccine; 2009 May; 27(24):3223-7. PubMed ID: 19446195
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
    De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH
    Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Meningococcal vaccine for adolescents and college freshmen.
    FDA Consum; 2005; 39(5):4. PubMed ID: 16421984
    [No Abstract]   [Full Text] [Related]  

  • 70. Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine.
    Sakou II; Tzanakaki G; Tsolia MN; Sioumala M; Barbouni A; Kyprianou M; Papaevangelou V; Tsitsika A; Blackwell CC; Kafetzis D; Kremastinou J
    Vaccine; 2009 Jul; 27(33):4408-11. PubMed ID: 19500554
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Expanding prevention of invasive meningococcal disease.
    Pelton SI; Gilmet GP
    Expert Rev Vaccines; 2009 Jun; 8(6):717-27. PubMed ID: 19485753
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Meningococcal C conjugate vaccination recommendations for infants. An Advisory Committee Statement (ACS).
    National Advisory Committee on Immunization (NACI)
    Can Commun Dis Rep; 2007 Nov; 33(ACS-11):1-12. PubMed ID: 18064747
    [No Abstract]   [Full Text] [Related]  

  • 73. Effectiveness of a trivalent serogroup A/C/W135 meningococcal polysaccharide vaccine in Burkina Faso, 2003.
    Soriano-Gabarró M; Toé L; Tiendrebeogo SR; Nelson CB; Dabal M; Djingarey MH; Plikaytis B; Rosenstein N;
    Vaccine; 2007 Sep; 25 Suppl 1():A92-6. PubMed ID: 17517451
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand.
    Lennon D; Jackson C; Wong S; Horsfall M; Stewart J; Reid S
    Clin Infect Dis; 2009 Aug; 49(4):597-605. PubMed ID: 19622040
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Update on influenza A (H1N1) 2009 monovalent vaccines.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Oct; 58(39):1100-1. PubMed ID: 19816398
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Adolescent Tdap vaccine use among primary care physicians.
    Dempsey AF; Cowan AE; Broder KR; Kretsinger K; Stokley S; Clark SJ
    J Adolesc Health; 2009 Apr; 44(4):387-93. PubMed ID: 19306798
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the Infectious Diseases Society of America.
    Pickering LK; Baker CJ; Freed GL; Gall SA; Grogg SE; Poland GA; Rodewald LE; Schaffner W; Stinchfield P; Tan L; Zimmerman RK; Orenstein WA;
    Clin Infect Dis; 2009 Sep; 49(6):817-40. PubMed ID: 19659433
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Vaccine prevention of meningococcal disease: making slow progress.
    Harrison LH
    Clin Infect Dis; 2006 Dec; 43(11):1395-7. PubMed ID: 17083010
    [No Abstract]   [Full Text] [Related]  

  • 79. Risk of Guillain-Barré syndrome following serogroup C meningococcal conjugate vaccine in Quebec, Canada.
    De Wals P; Deceuninck G; Boucher RM; Ouakki M
    Clin Infect Dis; 2008 Apr; 46(8):e75-7. PubMed ID: 18444843
    [TBL] [Abstract][Full Text] [Related]  

  • 80. ACIP recommends meningococcal vaccine for adolescents and college freshmen.
    Mich Med; 2005; 104(4):22. PubMed ID: 16053236
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.